| Search by tag or site | Login to my blog ? Start my own blog |
 |
BioHealth InvestorBioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network. |
Johnson & Johnson And Amgen: The Drug Marketing Blues
Posted on 03/13/2007 18:13 PM | Link | Post Comment
by Doulas A. McIntyre
24/7 Wall St.
Amgen (AMGN) got called in on the carpet for not make clear that a couple of its drugs had big time side effect. According to The Associated Press: "the FDA added warnings to the labels of Amgen's anemia drugs Epogen and Aranesp." Why?" Recent studies have shown that using too much of the drugs increased the risk of death, blood clots, strokes and heart attacks in patients with chronic kidney failure " Amgen's stock is near its 52-week low trading at $50.47, but Wall St. should ask why a company would wait for the FDA to call it in on the carpet. Wall St. hates it when the government gets involved in anyone business. And, the FDA can't get much more involved that this.
That lesson seems not have been learned at Johnson & Johnson (JNJ). The Feds paid them a visit, too. In this case according to the AP: "Johnson & Johnson said it has received subpoenas from federal prosecutors in Philadelphia, Boston and San Francisco related to the sales and marketing of three drugs. The drugs at issue are Risperdal, a treatment for schizophrenia and bipolar mania, the epilepsy treatment Topamax, and Natrecor, which is used to treat heart-failure patients, the New Brunswick, N.J., company said".
In the JNJ case the concern is that the drugs are being marketed to doctors for uses beyond those approved by the FDA.
But, wait a minute. In both cases the companies must have been on top of these issues. And, they let time pass. Now each is faced with the embarrassment of protracted examination of its business practices, and, perhaps, sanctions.
Not bright business practices.
Source: 247WallSt.com
RELATED READING:
- Biotech Daily Review: Amgen Must Post Black Box Warning
- Amgen: Large Cap Biotech with Growth Ahead
____________________
24/7 Wall St.
Amgen (AMGN) got called in on the carpet for not make clear that a couple of its drugs had big time side effect. According to The Associated Press: "the FDA added warnings to the labels of Amgen's anemia drugs Epogen and Aranesp." Why?" Recent studies have shown that using too much of the drugs increased the risk of death, blood clots, strokes and heart attacks in patients with chronic kidney failure " Amgen's stock is near its 52-week low trading at $50.47, but Wall St. should ask why a company would wait for the FDA to call it in on the carpet. Wall St. hates it when the government gets involved in anyone business. And, the FDA can't get much more involved that this.
That lesson seems not have been learned at Johnson & Johnson (JNJ). The Feds paid them a visit, too. In this case according to the AP: "Johnson & Johnson said it has received subpoenas from federal prosecutors in Philadelphia, Boston and San Francisco related to the sales and marketing of three drugs. The drugs at issue are Risperdal, a treatment for schizophrenia and bipolar mania, the epilepsy treatment Topamax, and Natrecor, which is used to treat heart-failure patients, the New Brunswick, N.J., company said".
In the JNJ case the concern is that the drugs are being marketed to doctors for uses beyond those approved by the FDA.
But, wait a minute. In both cases the companies must have been on top of these issues. And, they let time pass. Now each is faced with the embarrassment of protracted examination of its business practices, and, perhaps, sanctions.
Not bright business practices.
Source: 247WallSt.com
RELATED READING:
- Biotech Daily Review: Amgen Must Post Black Box Warning
- Amgen: Large Cap Biotech with Growth Ahead
____________________
- Mri To Lead Growth In Medical-imaging Market
- Malaria And Hiv - Eradication And Treatment
- Dragon’s New Production Process To Cut Costs
- Mrsa Update: Cepheid, Basilea And Nektar
- If Only Us Health Care Could Be More Like The Patriots (or Even The Red Sox) And Less Like The Yankees
- Credit Bloggers
- The Average Joe Investor
- Wishing Wealth
- Financial Skeptic
- Edmonton Real Estate
- Don't Mess With Taxes
Examples
Morpheus Trading - Mon Jul 21, 2008 08:33AM
NOTE: Please click on the charts below to enlarge them if [read more]
NOTE: Please click on the charts below to enlarge them if [read more]
Morpheus Trading - Mon Jul 21, 2008 08:31AM
NOTE: Please click on the charts below to enlarge them i [read more]
NOTE: Please click on the charts below to enlarge them i [read more]
Millionaire Now! by Larry Nusbaum - Tue Jul 22, 2008 09:23AM
Hedge funds have made billions this year shorting the banks, [read more]
Hedge funds have made billions this year shorting the banks, [read more]
<< My Home | TheMoneyBlogs Home